NEW YORK (360Dx) – Roche said today that it has obtained CE marking for the Ventana anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer patients eligible for treatment with the Novartis drug Zykadia (ceritinib).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.